Mankind Pharma Ltd Sees Sharp Open Interest Surge Amid Volatile Trading

Open Interest and Volume Dynamics

The latest data reveals that Mankind Pharma’s open interest in derivatives jumped by 7,327 contracts, a substantial 40.42% increase from the previous figure of 18,126 to 25,453. This surge in OI was accompanied by a robust trading volume of 40,843 contracts, indicating active participation from traders and investors. The futures segment alone accounted for a value of approximately ₹38,468.43 lakhs, while the options segment’s notional value stood at an impressive ₹22,242.59 crores, culminating in a total derivatives value of ₹42,957.11 lakhs.

The underlying stock price closed at ₹2,455, having experienced a notable intraday low of ₹2,422, down 5.97% on the day. The weighted average price of traded contracts clustered closer to the day’s low, suggesting that the bulk of trading activity occurred at lower price levels. This pattern often reflects bearish sentiment or profit-taking by short-term traders.

Price Performance and Market Context

Mankind Pharma’s stock underperformed its sector by 5.99% on the day, with a one-day return of -4.30% compared to the Pharmaceuticals & Biotechnology sector’s gain of 1.15%. The benchmark Sensex also posted a modest gain of 0.33%, underscoring the stock’s relative weakness. Notably, the stock has been on a downward trajectory for three consecutive sessions, losing 6.41% over this period, which may have contributed to the increased open interest as traders adjust their positions.

Despite the recent price weakness, the stock remains above its 100-day and 200-day moving averages, signalling that the longer-term trend is still intact. However, it trades below its 5-day, 20-day, and 50-day moving averages, indicating short- to medium-term pressure. Intraday volatility was high at 6.41%, reflecting uncertainty and active repositioning among market participants.

Investor Participation and Liquidity

Delivery volumes on 30 July stood at 1.67 lakh shares, slightly down by 0.47% compared to the five-day average delivery volume, suggesting a marginal decline in investor participation in the cash segment. Nevertheless, liquidity remains adequate, with the stock’s average traded value supporting trade sizes of up to ₹1.8 crore comfortably, making it accessible for institutional and retail traders alike.

Interpreting the Open Interest Surge

The sharp rise in open interest alongside elevated volumes suggests that new positions are being established rather than existing ones being squared off. This can indicate increased conviction among traders regarding the stock’s near-term direction. Given the recent price decline and clustering of trades near the intraday low, it is plausible that market participants are positioning for further downside or hedging existing long exposures.

However, the sizeable notional value in options contracts points to a complex mix of strategies, including protective puts, speculative calls, and spreads. The large open interest build-up in options could also imply that traders are anticipating heightened volatility or a potential reversal, using options to manage risk or capitalise on directional moves.

Mojo Score Upgrade and Market Sentiment

Mankind Pharma’s Mojo Score currently stands at 72.0, reflecting a positive outlook with a Buy grade. This marks an upgrade from the previous Hold rating as of 29 July 2026, signalling improved fundamentals and market positioning. The mid-cap stock’s market capitalisation is ₹1,01,811.77 crore, placing it firmly within the mid-cap segment of the Pharmaceuticals & Biotechnology sector.

Despite the recent price softness, the upgrade suggests that analysts see value in the stock’s longer-term prospects, possibly driven by robust earnings growth, product pipeline strength, or favourable sector dynamics. The divergence between the technical weakness and fundamental upgrade may be attracting opportunistic traders, contributing to the open interest surge.

Potential Directional Bets and Outlook

Given the data, market participants appear to be taking mixed directional bets. The increase in open interest and volume at lower price levels could indicate a build-up of short positions or protective hedges. Conversely, the sustained presence above key long-term moving averages and the Mojo upgrade may encourage some investors to accumulate on dips, expecting a rebound.

Traders should monitor the evolution of open interest in the coming sessions, particularly the ratio of call to put contracts and changes in strike price concentrations, to better gauge market sentiment. Additionally, tracking delivery volumes and price action relative to moving averages will provide further clues on whether the current weakness is a correction or the start of a deeper downtrend.

Conclusion

The recent surge in open interest for Mankind Pharma Ltd’s derivatives contracts highlights a period of active repositioning and heightened market interest amid a volatile price environment. While the stock has underperformed in the short term, the fundamental upgrade and sustained long-term technical support suggest that investors are weighing both risks and opportunities carefully.

For traders and investors, the evolving derivatives landscape offers valuable insights into market sentiment and potential directional bets. Close attention to open interest trends, volume patterns, and price action will be crucial in navigating the stock’s near-term trajectory within the broader Pharmaceuticals & Biotechnology sector.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →